{"prompt": "['Placebo-Controlled Study-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', 'c.', 'Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.', 'd.', 'Patient has clinically significant depression at screening or baseline.', 'Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks', 'before screening.', 'e.', 'Patient has a history of suicidal intent or related behaviors within 2 years of screening:', '- previous intent to act on suicidal ideation with a specific plan, irrespective of level of', 'ambivalence, at the time of suicidal thought', '-', 'previous suicidal preparatory acts or behavior', 'f.', 'Patient has a history of a previous actual, interrupted, or aborted suicide attempt.', 'g.', 'Patient has a first-degree relative who has completed suicide.', 'h.', 'Patient has clinically significant OCD at baseline that, in the opinion of the investigator, is the primary', 'cause of impairment.', 'i.', 'Patient has received CBIT for TS or CBT for OCD within 4 weeks of screening.', 'j.', 'Patient has received any of the following concomitant medications for tics within the specified', 'exclusionary windows of first dose:', '-', 'within 3 months: depot neuroleptics, botulinum toxin, or tetrabenazine', '-', 'within 4 weeks: cannabidiol oil and valbenazine', '-', 'within 21 days: reserpine', '-', 'within 14 days: neuroleptics (oral), typical and atypical antipsychotics (see Appendix A),', 'metoclopramide, levodopa, and dopamine agonists', 'Note: Use of stimulant medications, including amphetamine, methylphenidate, and', 'lisdexamfetamine, is allowed if primary use is for the treatment of ADHD, dosing has been stable', 'for at least 2 weeks before screening, and no changes to dose or frequency are anticipated during', 'the course of the study.', 'Note: Use of atomoxetine is allowed if the primary use is for the treatment of ADHD, dosing has', 'been stable for at least 4 weeks before screening, and no changes to dose or frequency are', 'anticipated during the course of the study.', 'Note: Use of benzodiazepines is allowed if primary use is not for tics and dosing has been stable', 'for at least 4 weeks before screening.', 'Note: Use of topiramate (up to 200 mg/day) is allowed if dosing has been stable for at least', '4 weeks before screening.', '-', 'Note: Use of guanfacine or clonidine is allowed regardless of indication (ie, if prescribed for ties', 'or Tourette syndrome) if the dosing has been stable for at least 4 weeks before screening and no', 'changes to dose or frequency are anticipated during the course of the study. If discontinuation of', 'either medication is anticipated due to ineffectiveness, poor tolerability, or patient/caregiver', 'preference, discontinuation should occur 4 or more weeks prior to the screening visit.', 'k.', 'Patient has received treatment with deep brain stimulation, or transmagnetic stimulation, or', 'transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit.', '1.', 'Patient has an unstable or serious medical illness at screening or baseline', '16']['Placebo-Controlled tudy-Tourette Syndrome', 'Clinical Study Protocol with Amendment 05', 'Study TV50717-CNS-30046', \"m. Patient has a QT interval corrected for heart rate using Fridericia's formula (QTcF) interval value\", '>450 msec (males) or >460 msec (females) or >480msec (with right bundle branch block) on 12-lead', 'ECG at screening, OR requires treatment with drugs known to prolong the QT interval (see', 'Appendix A, Table 6 for a complete list of prohibited QT-prolonging drugs).', 'n.', 'Patients with a history of torsade de pointes, congenital long QT syndrome, bradyarrhythmias, or', 'uncompensated heart failure.', 'o.', 'Patient has evidence of hepatic impairment, as indicated by:', '-', 'aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 X the upper limit of', 'the normal range (ULN) at screening', '-', 'alkaline phosphatase (ALP) or total bilirubin (Tbil) >2 X ULN at screening', \"Note: Patients with Gilbert's Syndrome are eligible to participate if approved by the medical\", 'monitor.', 'Note: Patients with abnormalities in 2 or more of the following clinical laboratory parameters', 'must be approved for enrollment by the medical monitor: AST, ALT, ALP, and Tbil.', 'p.', 'Patient has evidence of clinically significant renal impairment, indicated by a serum creatinine', '>1.5 X ULN at screening.', 'q. Patient has received a monoamine oxidase inhibitor within 14 days of the baseline visit.', 'r.', 'Patient has a known allergy to any of the components of the IMP.', 'S.', 'Patient has participated in an investigational drug or device study and received IMP/intervention', 'within 30 days or 5 drug half-lives of baseline, whichever is longer.', 't.', 'The patient is a pregnant or lactating female or plans to become pregnant during the study.', 'u.', 'Patient has a history of or acknowledges alcohol-related disorder in the previous 12 months, as defined', 'in the DSM-VTM', 'V. Patient has a positive urine drug screen test result or is unable to refrain from substance abuse', 'throughout the study.', 'W. Patient has a DSM diagnosis based on the MINI Kid Inventory modules performed at screening that, in', 'the opinion of the investigator, makes the patient unsuitable for the study.', 'Measures and Time Points:', 'Primary Efficacy Measures and Time Points: YGTSS (to calculate TTS): Screening; baseline; and weeks 2,', '4, 6, 9, 12, and 13', 'Key Secondary Efficacy Measures and Time Points:', '1. TS-CGI: baseline and weeks 2, 4, 6, 9, 12, and 13', '2. TS-PGII: baseline and weeks 2, 4, 6, 9, 12, and 13', '3.', 'C&A-GTS-QOL ADL subscale: baseline, week 6, and week 12', 'Exploratory Measures and Time Points:', '17']\n\n###\n\n", "completion": "END"}